NIH will partner drug industry to study Alzheimer’s, diabetes, and autoimmune disorders

BMJ 2014; 348 doi: (Published 06 February 2014) Cite this as: BMJ 2014;348:g1397
  1. Michael McCarthy
  1. 1Seattle

The US National Institutes of Health (NIH) will partner 10 biopharmaceutical companies to identify promising drug targets and disease biomarkers, the agency announced on 4 February. Eight nonprofit organizations will also participate in the collaboration.

The initiative, called the Accelerating Medicines Partnership, will initially focus on biomarkers and drug targets for Alzheimer’s disease, type 2 diabetes, and the autoimmune disorders of rheumatoid arthritis and systemic erythematosus.

All data and analyses generated by the initiative will be made publicly available “to the broad biomedical community,” the NIH said.

In a …

View Full Text

Log in

Log in through your institution


* For online subscription